<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951429</url>
  </required_header>
  <id_info>
    <org_study_id>MA29957</org_study_id>
    <secondary_id>2015-005131-40</secondary_id>
    <nct_id>NCT02951429</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension</brief_title>
  <official_title>A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Group 3 Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This Phase IIb, randomized, placebo-controlled, multicenter, international study will
      evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone
      (Esbriet) treatment in participants with advanced IPF and risk of Group 3 pulmonary
      hypertension (PH) who are on a stable dose of pirfenidone with demonstrated tolerability.
      Participants will be randomized to receive 1 year of treatment with either oral sildenafil or
      matching placebo while continuing to take pirfenidone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (&gt;=) 15 Percent (%) From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS), Defined as Time to Decline in 6MWD of &gt;=15% From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Decline From Baseline in 6MWD of &gt;= 15%</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Respiratory-Related Non-Elective Hospitalization</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to All-Cause Non-Elective Hospitalization</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death From Any Cause</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Respiratory-Related Death</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Lung Transplantation</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Peak Tricuspid Regurgitation Velocity</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in ECHO Parameter: Pulmonary Artery Pressure (PAPs)</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in FEV1/FVC Ratio</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Carbon Monoxide Diffusing Capacity/ Pulmonary Diffusing Capacity (DLCO)</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 6, 12, 26, 39, and 52 in Oxyhemoglobin Saturation (SpO2) at Rest and During the 6MWT</measure>
    <time_frame>Baseline, Weeks 6, 12, 26, 39, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Exertion, as Assessed by Borg Rating of Perceived Exertion Scale</measure>
    <time_frame>Baseline, Weeks 6, 12, 26, 39, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by World Health Organization (WHO) Functional Class</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 19, 26, 32, 39, 45, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 12, 26, 39, and 52 in Dyspnea, as Assessed by the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)</measure>
    <time_frame>Baseline, Weeks 12, 26, 39, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 12, 26, 39, and 52 in Health-Related Quality of Life (HRQoL), as Assessed by the Saint George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Baseline, Weeks 12, 26, 39, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 12, 26, and 52 in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) Level</measure>
    <time_frame>Baseline, Weeks 12, 26, and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>Baseline up to 108 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Pirfenidone + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone + Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.</description>
    <arm_group_label>Pirfenidone + Placebo</arm_group_label>
    <arm_group_label>Pirfenidone + Sildenafil</arm_group_label>
    <other_name>Esbriet, RO0220912</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched with sildenafil.</description>
    <arm_group_label>Pirfenidone + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil will be given as 20 mg, TID.</description>
    <arm_group_label>Pirfenidone + Sildenafil</arm_group_label>
    <other_name>RO0280296</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IPF for at least 3 months prior to Screening

          -  Confirmation of IPF diagnosis by the investigator in accordance with the 2011
             international consensus guidelines at screening

          -  Advanced IPF (defined as a measurable carbon monoxide diffusing capacity [DLCO] less
             than or equal to (&lt;=)40% of predicted value at Screening) and risk of group 3
             pulmonary hypertension (PH)

          -  Participants receiving pirfenidone for at least 12 weeks, at a dose in the range of
             1602 to 2403 mg/day for at least 4 weeks prior to Screening and must not have
             experienced either a new or ongoing adverse event of National Cancer Institute Common
             Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.03) Grade 2 or higher
             and considered by the investigator to be related to pirfenidone, or an interruption of
             pirfenidone treatment of greater than (&gt;)7 days for any reason

          -  WHO Functional Class II or III at Screening

          -  6MWD of 100 to 450 meters at screening

          -  Women of childbearing potential and for men who are not surgically sterile agreement
             to remain abstinent or use of contraceptive measures

        Exclusion Criteria:

          -  History of any of the following types of PH: Group 1 (PAH); Group 1 (pulmonary
             veno-occlusive disease and/or pulmonary capillary hemangiomatosis); Group 2
             (left-heart disease); Group 3 (due to conditions other than interstitial lung disease,
             including chronic obstructive pulmonary disease [COPD], sleep-disordered breathing,
             alveolar hypoventilation, high altitude, or developmental abnormalities); Group 4
             (chronic thromboembolic pulmonary hypertension); Group 5 (other disorders)

          -  History of clinically significant cardiac disease

          -  History of coexistent and clinically significant COPD, bronchiectasis, asthma,
             inadequately treated sleep-disordered breathing, or any clinically significant
             pulmonary diseases or disorders other than IPF or PH secondary to IPF

          -  History of use of drugs and toxins known to cause PAH, including aminorex,
             fenfluramine, dexenfluramine, and amphetamines

          -  FEV1/FVC ratio less than (&lt;) 0.70 post bronchodilator; SpO2 saturation at rest &lt;92%
             with &gt;= 6 liters (L) of supplemental oxygen at Screening

          -  Extent of emphysema greater than the extent of fibrotic changes (honeycombing and
             reticular changes) on any previous high-resolution computed tomography (HRCT) scan, in
             the opinion of the Investigator

          -  Smoked tobacco within 3 months prior to screening or is unwilling to avoid tobacco
             products (cigarettes, pipe, cigars) throughout the study

          -  Illicit drug or significant alcohol abuse

          -  Electrocardiogram (ECG) with a heart-rate corrected QT interval (corrected using
             Fridericia's formula [QTcF]) &gt;=500 milliseconds (ms) at screening, or a family or
             personal history of long QT syndrome

          -  Exclusion criteria based on pirfenidone reference safety information: 1. participants
             with a history of angioedema due to pirfenidone; 2. concomitant use of fluvoxamine

          -  Exclusion criteria based on sildenafil reference safety information: 1.
             co-administration with nitric oxide donors or organic nitrates, phosphodiesterase-5
             (PDE5) inhibitors, guanylate cyclase stimulators, and most potent of the Cytochrome
             P450 3A4 (CYP3A4) inhibitors; 2. loss of vision in one eye because of non-arteritic
             anterior ischemic optic neuropathy (NAION); 3. participants with bleeding disorders or
             active peptic ulceration; 4. known hereditary degenerative retinal disorders such as
             retinitis pigmentosa; 5. galactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: MA29957 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ULB Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU UCL Mont-Godinne</name>
      <address>
        <city>Mont-godinne</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUM Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec (Hôpital Laval)</name>
      <address>
        <city>Ste. Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice; Pneumologicka klinika 1.LF UK TN</name>
      <address>
        <city>Praha 4 - Krc</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center (CRC), Faculty of Medicine, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <zip>21561</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kasr El-Aini-Chest Unit; Department 3-Chest Unit</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ain Shams University Hospital-Chest unit; Chest unit</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Coswig GmbH Zentrum f.Pneumologie Beatmungsmedizin Thorax-u.Gefäßchirurgie</name>
      <address>
        <city>Coswig</city>
        <zip>01640</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik Donaustauf Zentrum für Pneumologie</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik Lungenzentrum der UNI Essen Abt.Pneumologie-Allergologie</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG; Universitätsmedizin Marburg, Campus Fulda</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Standort Gießen Medizinische Klinik II u. Poliklinik Innere Med./Pneumologie</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg gGmbH</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fachklinik für Lungenerkrankungen</name>
      <address>
        <city>Immenhausen</city>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Athens &quot;Attikon&quot;, B' University Pulmonary Clinic</name>
      <address>
        <city>Chaidari</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklio, Pulmonary Clinic</name>
      <address>
        <city>Heraklio</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orszagos Koranyi TBC es Pulmonologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem X; Pulmonologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soroka; Pulmonary Clinic</name>
      <address>
        <city>Beer Sheba</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center; Pulmonary Institute</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center; Pulmonary Inst.</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center; Pulmonary Institute</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center; Pulmonary Dept</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beilinson Medical Center; Pulmonary Inst.</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>7661041</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni-Pierantoni; U.O. Pneumologia</name>
      <address>
        <city>Forlì</city>
        <state>Emilia-Romagna</state>
        <zip>47121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Di Modena; DIP. Malattie Dell'apparato Respiratorio</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe; U.O. di Pneumologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST DI MONZA; U O Clinica Pneumologica</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Ospedali Riuniti Di Foggia-Ospedale D'avanzo; Malattie Dell'apparato Respiratorio IV</name>
      <address>
        <city>Foggia</city>
        <state>Puglia</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Vittorio Emanuele; Centro per la cura delle Malattie Rare del Polmone</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Univ. Senese Policlinico S. Maria alle Scotte; UOC Malattie Resepiratorie e Trapianto Polmonare</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova; Dip. Scienze Cardiologiche Toraciche Vascolari-UOC Pneumologia</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vu Medisch Centrum; Afdeling Longziekten</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cape Town Lung Institute; Lung Clinical Research</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Milpark Hospital</name>
      <address>
        <city>Parktown West</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Stellenbosch; Respiratory Research</name>
      <address>
        <city>Parow</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge ; Servicio de Neumologia</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08097</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de neumologia</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda; Servicio de Neumología</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I provincial; Servicio de Neumologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal;Servicio de Neumología</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Neumologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara Uni Faculty of Medicine; Chest Diseases</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uludag University; Pulmonology and Allergy Department</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yedikule Gogus Hastaliklari ve Gogus Cerrahisi EAH;Gogus Hastaliklari</name>
      <address>
        <city>Istanbul</city>
        <zip>34020</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Capa Tıp Fakültesi; Gogus Hastalıkları Anabilim dalı</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tıp Fakültesi; Gögüs Hastalıkları Bilim Dalı</name>
      <address>
        <city>İzmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tawam Hospital</name>
      <address>
        <city>Al Ain</city>
        <zip>15258</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Al Ain Hospital</name>
      <address>
        <city>Al Ain</city>
        <zip>P.O.Box 1006</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

